Literature DB >> 22525388

One hundred years of immunotherapy: review of the first landmark studies.

Désirée E S Larenas Linnemann1.   

Abstract

In 2011, one hundred years of allergen immunotherapy was celebrated. Several landmark studies date from the first decades of experience with this treatment and are still cited today, often without analysis of the original articles. Original articles of the oldest landmark studies on subcutaneous immunotherapy (SCIT) and sublingual immunotherapy were sought and reviewed in detail, together with some publications on their authors' historical background. Details that might be of importance to the present allergists are highlighted in this article. Study design, preparation of allergen extracts used for immunotherapy and clinical findings of the following studies are discussed. For the European school, Noon 1911 was the first report of successful application of grass pollen extract; Frankland 1954 was the first double-blind placebo-controlled randomized trial (DBPC-RCT) in SCIT. For the European school: Noon published the first report of successful application of grass pollen extract (1911); Frankland was the first double-blind placebo-controlled randomized trial (DBPC-RCT) in SCIT (1954). For the American line: Clowes published the first successful trial of ragweed SCIT (1913); Cooke used skin prick testing as diagnostic method (1915); Loveless used venom immunotherapy with purified venom (not whole body extract) (1956); in 1961/1968 Johnstone showed in a DBPC-RCT dose-effect of an allergen mix and highly significant asthma reduction after up to 14 yrs of treatment of asthmatic children; Lowell and Franklin did the first DB-RCT demonstrating ragweed pollen efficacy as part of a multi-allergen mix and 1967 ragweed pollen extract dose response. We discuss the first studies for SLIT in 1927 from Black (oral-IT versus SCIT) and 1986 from Scadding, DBPC-RCT with house dust mite extract. We conclude that an in-depth review of investigators' observations, methods, and thoughts, however, can also be enriching for investigators in the field today.

Entities:  

Mesh:

Year:  2012        PMID: 22525388     DOI: 10.2500/aap.2012.33.3515

Source DB:  PubMed          Journal:  Allergy Asthma Proc        ISSN: 1088-5412            Impact factor:   2.587


  6 in total

1.  International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis.

Authors:  Sarah K Wise; Sandra Y Lin; Elina Toskala; Richard R Orlandi; Cezmi A Akdis; Jeremiah A Alt; Antoine Azar; Fuad M Baroody; Claus Bachert; G Walter Canonica; Thomas Chacko; Cemal Cingi; Giorgio Ciprandi; Jacquelynne Corey; Linda S Cox; Peter Socrates Creticos; Adnan Custovic; Cecelia Damask; Adam DeConde; John M DelGaudio; Charles S Ebert; Jean Anderson Eloy; Carrie E Flanagan; Wytske J Fokkens; Christine Franzese; Jan Gosepath; Ashleigh Halderman; Robert G Hamilton; Hans Jürgen Hoffman; Jens M Hohlfeld; Steven M Houser; Peter H Hwang; Cristoforo Incorvaia; Deborah Jarvis; Ayesha N Khalid; Maritta Kilpeläinen; Todd T Kingdom; Helene Krouse; Desiree Larenas-Linnemann; Adrienne M Laury; Stella E Lee; Joshua M Levy; Amber U Luong; Bradley F Marple; Edward D McCoul; K Christopher McMains; Erik Melén; James W Mims; Gianna Moscato; Joaquim Mullol; Harold S Nelson; Monica Patadia; Ruby Pawankar; Oliver Pfaar; Michael P Platt; William Reisacher; Carmen Rondón; Luke Rudmik; Matthew Ryan; Joaquin Sastre; Rodney J Schlosser; Russell A Settipane; Hemant P Sharma; Aziz Sheikh; Timothy L Smith; Pongsakorn Tantilipikorn; Jody R Tversky; Maria C Veling; De Yun Wang; Marit Westman; Magnus Wickman; Mark Zacharek
Journal:  Int Forum Allergy Rhinol       Date:  2018-02       Impact factor: 3.858

2.  Decision-making analysis for allergen immunotherapy versus nasal steroids in the treatment of nasal steroid-responsive allergic rhinitis.

Authors:  Joshua L Kennedy; Derek Robinson; Jared Christophel; Larry Borish; Spencer Payne
Journal:  Am J Rhinol Allergy       Date:  2014 Jan-Feb       Impact factor: 2.467

Review 3.  Compromising between European and US allergen immunotherapy schools: Discussions from GUIMIT, the Mexican immunotherapy guidelines.

Authors:  Désirée Larenas-Linnemann; Noel Rodríguez-Pérez; Jorge A Luna-Pech; Mónica Rodríguez-González; María Virginia Blandón-Vijil; Blanca E Del-Río-Navarro; María Del Carmen Costa-Domínguez; Elsy Maureen Navarrete-Rodríguez; Carlos Macouzet-Sánchez; José Antonio Ortega-Martell; César Fireth Pozo-Beltrán; Alan Estrada-Cardona; Alfredo Arias-Cruz; Karen Guadalupe Rodríguez Galván; Herson Brito-Díaz; María Del Rosario Canseco-Raymundo; Enrique Emanuel Castelán-Chávez; Alberto José Escalante-Domínguez; José Luis Gálvez-Romero; Javier Gómez-Vera; Sandra Nora González-Díaz; María Gracia Belinda Guerrero-Núñez; Dante Daniel Hernández-Colín; Alejandra Macías-Weinmann; David Alejandro Mendoza-Hernández; Néstor Alejandro Meneses-Sánchez; María Dolores Mogica-Martínez; Carol Vivian Moncayo-Coello; Juan Manuel Montiel-Herrera; Patricia María O'Farril-Romanillos; Ernesto Onuma-Takane; Margarita Ortega-Cisneros; Lorena Rangel-Garza; Héctor Stone-Aguilar; Carlos Torres-Lozano; Edna Venegas-Montoya; Guillermo Wakida-Kusunoki; Armando Partida-Gaytán; Aída Inés López-García; Ana Paola Macías-Robles; María de Jesús Ambriz-Moreno; Amyra Ali Azamar-Jácome; Claudia Yusdivia Beltrán-De Paz; Chrystopherson Caballero-López; Juan Carlos Fernández de Córdova-Aguirre; José Roberto Fernández-Soto; José Santos Lozano-Sáenz; José Joel Oyoqui-Flores; Roberto Efrain Osorio-Escamilla; Fernando Ramírez-Jiménez; Daniela Rivero-Yeverino; Eric Martínez Infante; Miguel Alejandro Medina-Ávalos
Journal:  World Allergy Organ J       Date:  2020-08-21       Impact factor: 4.084

4.  Perennial is more effective than preseasonal subcutaneous immunotherapy in the treatment of seasonal allergic rhinoconjunctivitis.

Authors:  Damian Tworek; Malgorzata Bochenska-Marciniak; Izabela Kuprys-Lipinska; Maciej Kupczyk; Piotr Kuna
Journal:  Am J Rhinol Allergy       Date:  2013-04-29       Impact factor: 2.467

5.  Allergen-Specific Immunotherapy With Liposome Containing CpG-ODN in Murine Model of Asthma Relies on MyD88 Signaling in Dendritic Cells.

Authors:  Ricardo Wesley Alberca-Custodio; Lucas D Faustino; Eliane Gomes; Fernanda Peixoto Barbosa Nunes; Mirian Krystel de Siqueira; Alexis Labrada; Rafael Ribeiro Almeida; Niels Olsen Saraiva Câmara; Denise Morais da Fonseca; Momtchilo Russo
Journal:  Front Immunol       Date:  2020-04-23       Impact factor: 7.561

Review 6.  Immunotherapeutic strategies for sexually transmitted viral infections: HIV, HSV and HPV.

Authors:  Braira Wahid; Amjad Ali; Muhammad Idrees; Shazia Rafique
Journal:  Cell Immunol       Date:  2016-08-03       Impact factor: 4.868

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.